Novo Nordisk downgraded as pipeline ‘not poised to blunt semaglutide LOE’

Investing.com Gold reports: Novo Nordisk downgraded as pipeline ‘not poised to blunt semaglutide LOE’. This is a premium/paywalled source, so the brief is based on headline and available metadata only.